According to GlobalData, there will be 222,458 cases of melanoma by 2029 in the eight major markets (UK, US, France, Spain, Italy, Germany, Canada, and Australia). Credit: goodluz via Shutterstock.

The National Health Service (NHS) in the UK is funding nine trusts to pilot Skin Analytics’ artificial intelligence (AI) device for detecting cancerous skin legions. 

The Cambridge-based life sciences company developed the DERM, [Deep Ensemble for the Recognition of Malignancy] device to improve GPs’ diagnostic capabilities for potential skin cancers.  

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Utilising a smartphone-compatible device, the device captures dermoscopic images of skin lesions, which are then analysed by a deep learning algorithm that algorithm continuously improves its diagnostic accuracy through repeated analytical tasks. 

Manchester University NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, University Hospitals Dorset NHS Foundation Trust, and Dorset County Hospital NHS Foundation Trust are the first trusts to be granted the £2m ($2.54m) funding from the NHS England Cancer Programme to roll out DERM, which is already being used by 12 NHS trusts and primary care providers. 

According to a report on GlobalData’s Pharma Intelligence Center, the number of diagnosed incident cases of melanoma in the eight major markets (UK, US, France, Spain, Italy, Germany, Canada, and Australia) will grow by 16.61% from 190,771 cases in 2019 to 222,458 cases by 2029. 

See Also:

In the announcement accompanying the rollout, Skin Analytics CEO Neil Daly said: “DERM not only helps detect and assess potential cases of skin cancer but also eases pressure on routine patients seeking dermatology services. If successful, and we are confident it will be, we hope this rollout could pave the way for wider adoption across all NHS trusts in England, creating a standardised and efficient dermatology pathway.” 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Earlier this year, the US Food and Drug Administration (FDA) greenlit DermaSensor’s skin cancer detection device, following a pivotal study led by the Mayo Clinic, which enrolled over 1,000 patients across 22 study centres – demonstrating a 96% sensitivity rate for the device across 224 identified skin cancers.